CONTACT:
Julie Chase
Chase Communications
415-433-0100
415-710-7108 - cell
jchase@chasepr.com

SANTEN ANNOUNCES NEW VICE PRESIDENT OF STRATEGIC MARKETING & BUSINESS DEVELOPMENT

Schalon Newton Brings International Experience to Santen's U.S. Team

NAPA, Calif. -- (February 28, 2006) Santen Inc. President and CEO, Adrienne Graves, today announced Schalon Newton as Vice President of Strategic Marketing & Business Development. Newton joins Santen February 27th. Santen Inc. is the U.S. subsidiary of global ophthalmic pharmaceutical leader Santen Pharmaceutical Co. Ltd.

Newton has been involved in the international ophthalmic arena for more than 20 years, predominantly directing a number of Allergan divisions in the United States, Japan and Europe.

"We are focused on developing and delivering innovative global products in the areas of glaucoma, retina, and dry eye," says Adrienne Graves, Ph.D. "Schalon's extensive track record of building successful businesses and forming strategic alliances will be a great asset to Santen as we continue to identify the next generation of compounds to develop and market."

Prior to joining Santen, Newton held management positions with Allergan, Inc. in Finance, Sales and Marketing, General Management and Business Development. For most of his 21-year-tenure with Allergan he held positions in the international division. For nine years he resided overseas in France, England and Japan, where he was the President of Allergan's largest offshore subsidiary. He also served on the strategic advisory board of Ancile Pharmaceuticals in San Diego and most recently as Principal for Skopos Consulting Group, Inc., providing strategic and organization development consulting to a broad range of companies.

Newton holds an M.B.A. degree from the University of California, Berkeley with specialization in Strategic Marketing and Finance and a B.S. degree in Business

- more -

Administration from California State University, Northridge, with specialization in Marketing and Finance. Currently, he is a doctoral candidate at the Weatherhead School of Management, Case Western Reserve University, Cleveland, Ohio.

"I have tracked Santen for many years and have always been impressed by its global resources and outstanding staff," says Newton. "Their commitment to, and success within, the global ophthalmic market during the last century has been exceptional. Santen has world class R&D capabilities and exceptional clinical development capability in Japan, Europe and the U.S. and there is strategic intent to leverage these capabilities to build a strong commercial presence in the U.S. market. I am honored to have the opportunity to further develop Santen's U.S. business and support the company's overall strategy."

Santen Inc., based in Napa, California, is the U.S. subsidiary of Santen Pharmaceutical Co., Ltd., an $850 million global company headquartered in Osaka, Japan since1890. Santen researches, develops and markets ophthalmic products for physicians worldwide. Santen Ltd. has more than a 40% market share for ophthalmic pharmaceuticals in Japan, and has additional subsidiaries in Europe and Asia. For more information, visit www.santeninc.com.

#-#-#